Sugi Predict

Sugi Predict / Targets / MARK4

MARK4

MAP/microtubule affinity-regulating kinase 4 · Q96L34 · MARK4 on Sugi Atlas →

13,783 patent compounds predicted against MARK4, 10,024 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1355460 SCHEMBL1355460 0.52 4/20
SCHEMBL1355849 SCHEMBL1355849 0.48 4/20
Ucn-01 Ucn-01 (SCHEMBL259162) 1.00 3/20
Ucn-01 Ucn-01 (SCHEMBL1551632) 1.00 3/20
SCHEMBL1284996 SCHEMBL1284996 0.59 3/20
SCHEMBL914293 SCHEMBL914293 0.59 3/20
SCHEMBL1285266 SCHEMBL1285266 0.58 3/20
SCHEMBL912996 SCHEMBL912996 0.56 3/20
SCHEMBL913730 SCHEMBL913730 0.55 3/20
SCHEMBL914664 SCHEMBL914664 0.54 3/20
SCHEMBL270735 SCHEMBL270735 0.53 3/20
SCHEMBL913729 SCHEMBL913729 0.52 3/20
SCHEMBL913883 SCHEMBL913883 0.52 3/20
SCHEMBL1284580 SCHEMBL1284580 0.49 3/20
SCHEMBL1285556 SCHEMBL1285556 0.49 3/20
SCHEMBL1284711 SCHEMBL1284711 0.47 3/20
SCHEMBL1285158 SCHEMBL1285158 0.46 3/20
SCHEMBL1285345 SCHEMBL1285345 0.46 3/20
SCHEMBL1285231 SCHEMBL1285231 0.45 3/20
SCHEMBL1284874 SCHEMBL1284874 0.44 3/20

Clinical trials — most relevant to MARK4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Paliperidone and Lithium in the Treatment of Suicidality - Treatment Indication and Epigenetic Regulation PHASE4COMPLETED
Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients PHASE3ACTIVE_NOT_RECRUITING
Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients PHASE3COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU) PHASE2/PHASE3ACTIVE_NOT_RECRUITING
Safety and Efficacy of AAV9/AP4B1 (BFB-101) For Patients With AP4B1-related Hereditary Spastic Paraplegia Type 47 (SPG47) PHASE1/PHASE2NOT_YET_RECRUITING
Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt) PHASE1/PHASE2RECRUITING
Neoadjuvant Paclitaxel Plus Epirubicin Versus Vinorelbine Plus Epirubicin in Breast Cancer With TEKT4 Variations PHASE2COMPLETED
Pembrolizumab (MK-3475) in MM Patients With Residual Disease PHASE2COMPLETED
A Multicenter Study of NAP (AL-108) in Schizophrenia PHASE2COMPLETED
Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer PHASE2COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Nilotinib in Huntington's Disease PHASE1UNKNOWN
Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease. PHASE1COMPLETED
Far Infrared Irradiation for the Management, Control and Treatment of Frontotemporal Dementia PHASE1UNKNOWN
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer EARLY_PHASE1COMPLETED
Generating Intervals of Reference FFor Early Life Brain Biomarkers. nanRECRUITING
Evaluation of a Novel PET Radioligand to Image OGA nanCOMPLETED
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo nanUNKNOWN
Rostock International Parkinson's Disease Study (ROPAD) nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Susceptibility Genes in Autism Spectrum Disorders nanCOMPLETED
Immune Cell Response to Stimuli nanRECRUITING
Biomarkers in Samples From Patients With Endometrial Cancer nanWITHDRAWN
Protein Intake and Step Reduction in Older Adults nanCOMPLETED
Natural History, Pathogenesis and Outcome of Melorheostosis A Rare Osteosclerotic Disease nanRECRUITING
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors nanACTIVE_NOT_RECRUITING
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a MARK4 binder may also engage these)

ProteinNameSimilarity
Q8CIP4 — 1.000 Q8CIP4 →
Q5RJI5 — 0.996 Q5RJI5 →
B2DD29 — 0.995 B2DD29 →
BRSK1 Serine/threonine-protein kinase BRSK1 0.993 landscape →
Q3ULB5 — 0.991 Q3ULB5 →
MAP3K9 Mitogen-activated protein kinase kinase kinase 9 0.989 landscape →
O70405 — 0.989 O70405 →
Q68UT7 — 0.989 Q68UT7 →
Q66HE5 — 0.989 Q66HE5 →
Q9Z188 — 0.989 Q9Z188 →
Q05512 — 0.988 Q05512 →
Q641K5 — 0.988 Q641K5 →
Q63553 — 0.988 Q63553 →
MARK2 Serine/threonine-protein kinase MARK2 0.988 landscape →
D3ZML2 — 0.988 D3ZML2 →
Q3U214 — 0.987 Q3U214 →
Q8RXT4 — 0.987 Q8RXT4 →
O08679 — 0.987 O08679 →
Q9BQI7 — 0.987 Q9BQI7 →
Q80XI6 — 0.987 Q80XI6 →
Q66HA1 — 0.987 Q66HA1 →
Q5R8Z4 — 0.987 Q5R8Z4 →
Q03141 — 0.986 Q03141 →
Q3U1V8 — 0.986 Q3U1V8 →
Q6P1I6 — 0.986 Q6P1I6 →
Q8TDY4 — 0.986 Q8TDY4 →
Q8K3A9 — 0.986 Q8K3A9 →
DYRK1B Dual specificity tyrosine-phosphorylation-regulated kinase 1B 0.986 landscape →
Q8BTW9 — 0.986 Q8BTW9 →
A5PKJ4 — 0.986 A5PKJ4 →